Posted on 06/19/2023 1:41:14 PM PDT by ConservativeMind
Researchers found the KRAS G12C inhibitor adagrasib showed promising activity suppressing cancer growth not only within the lungs but also in brain metastases for patients with KRAS G12 C-mutated non-small cell lung cancer (NSCLC).
Findings from the Phase Ib cohort of the KRYSTAL-1 trial represent the first prospective data of anti-tumor activity from a KRAS G12C inhibitor in brain metastases, providing continued evidence of the drug's efficacy.
The targeted therapy showed an intracranial disease control rate of 90%. Additionally, researchers observed a 42% objective response rate (ORR) in shrinking tumors within the brain. The median intracranial progression-free survival (PFS) was 5.4 months, while the median overall survival (OS) reached 11.4 months.
KRAS mutations occur in approximately 25-30% of NSCLC cases, with the KRAS G12C mutation accounting for around 13% of these instances. While radiation therapy and surgery historically have been utilized to treat brain metastases, targeted drugs with central nervous system (CNS) penetration continue to demonstrate encouraging efficacy for treatment of brain metastases.
Adagrasib targets the mutated KRAS protein, inhibiting its ability to promote abnormal cancer cell growth. The drug has obtained approval from the FDA for the treatment of advanced KRAS G12C-mutant NSCLC in adult patients who have not responded to standard systemic therapy.
This study included 25 patients with KRAS G12C-mutated NSCLC and untreated CNS metastases from the Phase Ib portion of the ongoing KRYSTAL-1 trial. Most participants were female (52%) with a median age of 66 years and a predominant ethnic representation of individuals identifying as white. Participants were given oral adagrasib at a 600 mg dose, twice daily.
The systemic ORR in these patients was 30%. Median intracranial duration of response was 12.7 months. 37% of patients in the study saw progression of brain metastases, and only two patients saw progression in the CNS alone.
(Excerpt) Read more at medicalxpress.com ...
It wasn’t a cure, but 42% had shrinkage of brain tumors.
All that Tim Scott has to do is reply “You were elected President of the United States you whiny little bitch!”
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.